FLT3
FLT3 (fms related receptor tyrosine kinase 3, also known as CD135, STK1 and FLK2) is a class III receptor tyrosine kinase that acts as the cell-surface receptor for FLT3LG. It regulates the differentiation, proliferation and survival of haematopoietic progenitor cells and dendritic cells. Browse Assay Genie's current range of FLT3 research reagents below, or read on for the biology behind the target.
FLT3 is a tyrosine-protein kinase that functions as a cell-surface receptor for the cytokine FLT3LG. Binding of the ligand to the extracellular domain induces homodimer formation in the plasma membrane and autophosphorylation of the receptor. The activated kinase then phosphorylates and activates several cytoplasmic effector molecules, including SHC1 and AKT1, with activation of the downstream effector MTOR. It also promotes RAS signalling and phosphorylation of MAPK1/ERK2 and MAPK3/ERK1, as well as FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1 and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Through these pathways the receptor controls apoptosis, proliferation and differentiation of haematopoietic cells in bone marrow.
The FLT3 gene encodes a class III receptor tyrosine kinase. UniProt places it in the protein kinase superfamily, Tyr protein kinase family, CSF-1/PDGF receptor subfamily. HGNC groups it with CSF1R and KIT in a receptor tyrosine kinase family, and also lists it among the CD molecules and immunoglobulin-like domain containing proteins. The protein is found in the membrane and in the endoplasmic reticulum lumen. A mouse ortholog, Flt3, is recorded.
The gene has carried several names, including fms-related tyrosine kinase 3, STK1 and FLK2, and the protein is designated CD135. FLT3 is of particular interest in haematological malignancy. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis through the activation of multiple signalling pathways, and NCBI Gene reports that such activating mutations result in acute myeloid leukaemia and acute lymphoblastic leukaemia.
Constitutively activating FLT3 mutations are linked to acute myeloid leukaemia and acute lymphoblastic leukaemia, making the receptor central to studies of leukaemic proliferation.
FLT3 regulates differentiation, proliferation and survival of haematopoietic progenitor cells in bone marrow, so it is widely used to study blood-cell development.
The receptor regulates differentiation, proliferation and survival of dendritic cells, linking FLT3LG signalling to this immune cell lineage.
FLT3 activates SHC1, AKT1, MTOR, RAS, ERK1/2 and STAT5 signalling, offering a model for receptor tyrosine kinase signal transduction.
FLT3 is a cell-surface receptor tyrosine kinase for FLT3LG. Ligand binding induces dimerisation and autophosphorylation, activating pathways such as RAS/ERK, AKT/MTOR and PLCG1. This regulates differentiation, proliferation and survival of haematopoietic progenitor cells and dendritic cells.
FLT3 is also called CD135, STK1 and FLK2. Earlier HGNC names were fms-related tyrosine kinase 3 and fms related tyrosine kinase 3. UniProt lists the protein as receptor-type tyrosine-protein kinase FLT3, an enzyme with EC number 2.7.10.1.
Mutations that make FLT3 constitutively active drive cell proliferation and resistance to apoptosis through multiple signalling pathways. NCBI Gene associates these mutations with acute myeloid leukaemia and acute lymphoblastic leukaemia. The mouse ortholog is Flt3; check the datasheet of any product for its validated reactivity.
The cognate ligand of FLT3 and related signalling partners with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P36888; product specifications from Assay Genie datasheets.